Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–7.
Article CAS PubMed PubMed Central Google Scholar
Shen J, Wang Y, Yao K. Protection of retinal ganglion cells in glaucoma: current status and future. Exp Eye Res. 2021;205:108506.
Article CAS PubMed Google Scholar
Wiggs JL, Pasquale LR. Genetics of glaucoma. Hum Mol Genet. 2017;26(R1):R21–7.
Article CAS PubMed PubMed Central Google Scholar
Challa P, Schmidt S, Liu Y, et al. Analysis of LOXL1 polymorphisms in a United States population with pseudoexfoliation glaucoma. Mol Vis. 2008;14:146.
CAS PubMed PubMed Central Google Scholar
Rowan S, Jiang S, Korem T, et al. Involvement of a gut-retina axis in protection against dietary glycemia-induced age-related macular degeneration. Proc Natl Acad Sci U S A. 2017;114(22):E4472–81.
Article CAS PubMed PubMed Central Google Scholar
Li H, Ye Z, Li Z. Identification of the potential biological target molecules related to primary open-angle glaucoma. BMC Ophthalmol. 2022;22(1):188.
Article CAS PubMed PubMed Central Google Scholar
Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol. 2008;246(11):1593–601.
Lin HC, Chien CW, Hu CC, et al. Comparison of comorbid conditions between open-angle glaucoma patients and a control cohort: a case-control study. Ophthalmology. 2010;117(11):2088–95.
Yadav KS, Rajpurohit R, Sharma S. Glaucoma: current treatment and impact of advanced drug delivery systems. Life Sci. 2019;221:362–76.
Article CAS PubMed Google Scholar
Ma A, Yu SWY, Wong JKW. Micropulse laser for the treatment of glaucoma: a literature review. Surv Ophthalmol. 2019;64(4):486–97.
Lim R. The surgical management of glaucoma: a review. Clin Exp Ophthalmol. 2022;50(2):213–31.
Tezel G. The immune response in glaucoma: a perspective on the roles of oxidative stress. Exp Eye Res. 2011;93(2):178–86.
Article CAS PubMed Google Scholar
Tezel G. Immune regulation toward immunomodulation for neuroprotection in glaucoma. Curr Opin Pharmacol. 2013;13(1):23–31.
Article CAS PubMed Google Scholar
Tezel G, Wax MB. The immune system and glaucoma. Curr Opin Ophthalmol. 2004;15(2):80–4.
Coleman AL. Glaucoma. Lancet. 1999;354(9192):1803–10.
Article CAS PubMed Google Scholar
Saccà SC, Gandolfi S, Bagnis A, et al. From DNA damage to functional changes of the trabecular meshwork in aging and glaucoma. Ageing Res Rev. 2016;29:26–41.
Buffault J, Labbé A, Hamard P, et al. The trabecular meshwork: structure, function and clinical implications. A review of the literature. J Fr Ophtalmol. 2020;43(7):e217–30.
Article CAS PubMed Google Scholar
Zhang T, Xie X, Lu F. Primary open-angle glaucoma: neuroendocrine-immune disorder? Med Hypotheses. 2014;83(4):514–5.
Article CAS PubMed Google Scholar
Williams PA, Marsh-Armstrong N, Howell GR. Neuroinflammation in glaucoma: a new opportunity. Exp Eye Res. 2017;157:20–7.
Article CAS PubMed PubMed Central Google Scholar
Takiishi T, Fenero CIM, Câmara NOS. Intestinal barrier and gut microbiota: shaping our immune responses throughout life. Tissue Barriers. 2017;5(4):e1373208.
Article PubMed PubMed Central Google Scholar
Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124(4):837–48.
Article CAS PubMed Google Scholar
Chen Y, Zhou J, Wang L. Role and Mechanism of gut microbiota in human disease. Front Cell Infect Microbiol. 2021;11:625913.
Article CAS PubMed PubMed Central Google Scholar
Matsiras D, Bezati S, Ventoulis I et al. Gut failure: a review of the pathophysiology and therapeutic potentials in the gut-heart axis. J Clin Med. 2023;12(7):2567.
Peh A, O’donnell JA, Broughton BRS, et al. Gut microbiota and their metabolites in stroke: a double-edged sword. Stroke. 2022;53(5):1788–801.
Article CAS PubMed Google Scholar
Ahlawat S, Asha Sharma KK. Gut-organ axis: a microbial outreach and networking. Lett Appl Microbiol. 2021;72(6):636–68.
Article CAS PubMed Google Scholar
Trøseid M, Andersen G, Broch K, et al. The gut microbiome in coronary artery disease and heart failure: current knowledge and future directions. EBioMedicine. 2020;52:102649.
Article PubMed PubMed Central Google Scholar
Bubnov R, Golubnitschaja O. Flammer syndrome, disordered eating and microbiome: interrelations, complexity of risks and individual outcomes. In: Golubnitschaja O, editor. Flammer syndrome: from phenotype to associated pathologies, prediction, prevention and personalisation. Cham: Springer International Publishing; 2019. p. 317–30.
Floyd JL, Grant MB. The gut-eye axis: lessons learned from murine models. Ophthalmol Ther. 2020;9(3):499–513.
Article PubMed PubMed Central Google Scholar
Rowan S, Jiang S, Korem T, et al. Involvement of a gut–retina axis in protection against dietary glycemia-induced age-related macular degeneration. Proc Natl Acad Sci. 2017;114(22):E4472–81.
Article CAS PubMed PubMed Central Google Scholar
Yempén REA, Venzel R, Campos MCP, et al. Gut microbiota: a potential therapeutic target for management of diabetic retinopathy? Life Sci. 2021;286:120060.
Napolitano P, Filippelli M, Davinelli S, et al. Influence of gut microbiota on eye diseases: an overview. Ann Med. 2021;53(1):750–61.
Article CAS PubMed PubMed Central Google Scholar
Mcpherson ZE, Sorensen HT, Horvath-Puho E, et al. Irritable bowel syndrome and risk of glaucoma: an analysis of two independent population-based cohort studies. United Eur Gastroenterol J. 2021;9(9):1057–65.
Gong H, Zhang S, Li Q, et al. Gut microbiota compositional profile and serum metabolic phenotype in patients with primary open-angle glaucoma. Exp Eye Res. 2020;191:107921.
Article CAS PubMed Google Scholar
Gong H, Zeng R, Li Q, et al. The profile of gut microbiota and central carbon-related metabolites in primary angle-closure glaucoma patients. Int Ophthalmol. 2022;42(6):1927–38.
Golubnitschaja O, Bubnov R. Microbiome in Lean individuals: phenotype-specific risks and outcomes. In: Boyko N, Golubnitschaja O, editors. Microbiome in 3P medicine strategies: the first exploitation guide. Cham: Springer International Publishing; 2023. p. 87–99.
Bubnov R, Spivak M. Pathophysiology-based individualized use of probiotics and prebiotics for metabolic syndrome: implementing predictive, preventive, and personalized medical approach. In: Boyko N, Golubnitschaja O, editors. Microbiome in 3P medicine strategies: the first exploitation guide. Cham: Springer International Publishing; 2023. p. 133–96.
Reid G, Abrahamsson T, Bailey M, et al. How do probiotics and prebiotics function at distant sites? Benef Microbes. 2017;8(4):521–33.
Article CAS PubMed Google Scholar
Chen Q, Zhao B, Wang MY, et al. Associations between the red blood cell distribution width and primary angle-closure glaucoma: a potential for disease prediction. EPMA J. 2019;10(2):185–93.
Article PubMed PubMed Central Google Scholar
Li S, Qiu Y, Yu J, et al. Association of systemic inflammation indices with visual field loss progression in patients with primary angle-closure glaucoma: potential biomarkers for 3P medical approaches. EPMA J. 2021;12(4):659–75.
Article PubMed PubMed Central Google Scholar
Zhang Q, Wang N, Rui Y, et al. New insight of metabolomics in ocular diseases in the context of 3P medicine. EPMA J. 2023;14(1):53–71.
Comments (0)